OCTREOTIDE ACETATE - Generic Drug Details

What are the generic sources for octreotide acetate and what is the scope of freedom to operate?

Octreotide acetate is the generic ingredient in seven branded drugs marketed by Chiesi, Fresenius Kabi Usa, Gland, Heritage, Meitheal, Mylan Labs Ltd, Sagent Pharms Inc, Shuangcheng, Sun Pharm Inds, Teva Pharms Usa Inc, West-ward Pharms Int, Wockhardt Usa, Mylan Institutional, Novartis, and Sun Pharm, and is included in twenty-seven NDAs. There are twenty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Octreotide acetate has eighty-eight patent family members in twenty-nine countries.

There are nineteen drug master file entries for octreotide acetate. Fourteen suppliers are listed for this compound.

Summary for OCTREOTIDE ACETATE

International Patents:	88
US Patents:	21
Tradenames:	7
Applicants:	15
NDAs:	27
Drug Master File Entries:	19
Finished Product Suppliers / Packagers:	14
Raw Ingredient (Bulk) Api Vendors:	53
Clinical Trials:	48
Drug Prices:	Drug price trends for OCTREOTIDE ACETATE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for OCTREOTIDE ACETATE
What excipients (inactive ingredients) are in OCTREOTIDE ACETATE?	OCTREOTIDE ACETATE excipients list
DailyMed Link:	OCTREOTIDE ACETATE at DailyMed

See drug prices for OCTREOTIDE ACETATE

Recent Clinical Trials for OCTREOTIDE ACETATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Columbia University	PHASE1
University of California, Berkeley	PHASE1
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)	PHASE1

See all OCTREOTIDE ACETATE clinical trials

Pharmacology for OCTREOTIDE ACETATE

Drug Class	Somatostatin Analog
Mechanism of Action	Somatostatin Receptor Agonists

Medical Subject Heading (MeSH) Categories for OCTREOTIDE ACETATE

Antineoplastic Agents, Hormonal

Gastrointestinal Agents

Anatomical Therapeutic Chemical (ATC) Classes for OCTREOTIDE ACETATE

H01CB	Somatostatin and analogues
H01C	HYPOTHALAMIC HORMONES
H01	PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES
H	Systemic hormonal preparations, excluding sex hormones and insulins

Paragraph IV (Patent) Challenges for OCTREOTIDE ACETATE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
MYCAPSSA	Delayed-release Capsules	octreotide acetate	20 mg	208232	1	2023-12-29
SANDOSTATIN	Injection	octreotide acetate	0.05 mg/mL (base), 0.1 mg/mL (base) and 0.5 mg/mL (base) packaged in 1 mL pre-filled syringes (preservative-free)	019667	1	2008-01-17

US Patents and Regulatory Information for OCTREOTIDE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chiesi	MYCAPSSA	octreotide acetate	CAPSULE, DELAYED RELEASE;ORAL	208232-001	Jun 26, 2020		RX	Yes	Yes
Chiesi	MYCAPSSA	octreotide acetate	CAPSULE, DELAYED RELEASE;ORAL	208232-001	Jun 26, 2020		RX	Yes	Yes	9,265,812		Y
Fresenius Kabi Usa	OCTREOTIDE ACETATE	octreotide acetate	INJECTABLE;INJECTION	077450-002	Feb 10, 2006	AP	RX	No	No

Expired US Patents for OCTREOTIDE ACETATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-001	Nov 25, 1998	5,753,618
Novartis	SANDOSTATIN LAR	octreotide acetate	INJECTABLE;INJECTION	021008-001	Nov 25, 1998	4,395,403
Novartis	SANDOSTATIN	octreotide acetate	INJECTABLE;INJECTION	019667-001	Oct 21, 1988	4,395,403

International Patents for OCTREOTIDE ACETATE

Country	Patent Number	Title	Estimated Expiration
European Patent Office	3210474	COMPOSITIONS PHARMACEUTIQUES COMPRENANT DES POLYPEPTIDES ET PROCÉDÉS ASSOCIÉS D'ADMINISTRATION (PHARMACEUTICAL COMPOSITIONS COMPRISING POLYPEPTIDES AND RELATED METHODS OF DELIVERY)
Croatia	P20250645
Japan	2019048872	医薬組成物および関連する送達方法 (PHARMACEUTICAL COMPOSITION, AND RELATED DELIVERY METHOD)

Octreotide Acetate: Market Dynamics and Financial Trajectory

Last updated: May 11, 2026

What is the current market structure for octreotide acetate?

Octreotide acetate is a long-established somatostatin analog used across endocrine and GI indications, with commercial demand concentrated in two product classes: (1) immediate-release (IR) octreotide acetate for short-acting control and (2) long-acting depot formulations that drive repeat dosing economics and formulary stickiness.

Key market dynamic: demand shifts toward long-acting depot products because they reduce dosing frequency and improve adherence. This typically raises commercial resilience versus IR products, which remain more exposed to pharmacy-level switching and price competition.

Competitive landscape pattern:

• Originator anchors: branded long-acting octreotide depots historically set market pricing and reimbursement benchmarks.
• Generic penetration: generics expand primarily after exclusivity windows close for specific dosage forms and jurisdictions, with greater impact in IR strengths and settings where payer formularies allow substitution.
• Biosurveillance and substitution constraints: although octreotide is a small molecule, formulation-specific substitutability is often more constrained in depot products, slowing generic capture compared with IR.

How has demand behaved across dosing forms and indications?

Octreotide acetate demand is supported by ongoing treatment need in:

• Neuroendocrine tumors (NETs) and related hormone-secreting tumors where somatostatin analogs are standard-of-care in many lines.
• Acromegaly (where octreotide is used when surgery is not suitable or as part of disease control).
• Control of GI neuroendocrine symptoms and other hormone-mediated conditions.

Formulation-driven demand mechanics

• Depot formulations tend to show steadier revenue because dosing intervals are longer and patients remain on established regimens once stable.
• IR formulations typically see more volatility tied to shorter-term regimen changes and payer-driven switching.

What drives pricing and reimbursement pressure?

The commercial trajectory for octreotide acetate is shaped by:

• Exclusivity ending by product form and geography. Even when a molecule is mature, each branded depot and strength can face distinct patent and regulatory milestones.
• Payer policy favoring lower-cost substitutes. Where substitution is permitted, net pricing typically compresses after generic entry.
• Outcome-based alignment. Payers and providers evaluate comparative effectiveness within NET sequencing; where octreotide remains a core option, retention supports demand but still pressures unit price over time.

Net effect: revenue tends to migrate from premium-branded levels toward a blended mix of branded and lower-cost products after generic entry, with depot products cushioning declines.

How do patent and exclusivity cycles shape near-term economics?

Octreotide acetate commercial value follows the lifecycle of each specific dosage form (IR versus depot) and each market’s exclusivity architecture (patent term plus regulatory exclusivity). Once barriers fall for a given product and route of administration, the market typically experiences:

• rapid share gains by lower-priced versions,
• slower but persistent margin compression due to depot-specific formulary inertia,
• eventual convergence of pricing across strengths where substitution is straightforward.

What is the financial trajectory likely to look like from a market-sizing perspective?

Given maturity, octreotide acetate typically follows a staged revenue pattern:

1. Branded dominance phase (early and mid lifecycle): higher prices, high share, depot-heavy revenue.
2. Generic transition phase: unit price declines accelerate while depot share remains relatively sticky.
3. Maturity phase: the product category stabilizes in volume terms but with structurally lower net revenue per unit.

Expected directionality

• Top-line: volume can remain durable because NET and endocrine management are chronic.
• Revenue growth: slows as pricing declines offset any volume increases.
• Margin: compresses post-generic entry, with depot margins often more resilient than IR due to higher switching friction.

Where does octreotide acetate sit versus other somatostatin analogs economically?

Within somatostatin analog classes, octreotide competes on:

• dosing interval options (depot cadence),
• clinical positioning in NET pathways,
• payer formulary placement (net price bands),
• and availability of alternative long-acting agents.

Economic implication: even when octreotide’s clinical role persists, incremental formulary approvals for competing long-acting therapies can pressure pricing and share, especially in high-spend oncology cohorts.

What are the key market performance indicators for octreotide acetate?

For investment-grade monitoring of octreotide acetate’s market and financial trajectory, track these indicators:

KPI	What to watch	Why it matters
Depot-to-IR mix	Share shift toward depot formulations	Depot mix reduces pricing volatility and supports adherence-driven retention
Net price trends	Declines after generic entry by geography and strength	Generic transitions drive margin compression
Formulary status	Position within NET endocrine and GI symptom pathways	Formulary changes alter switching rates and volume
Patient persistence	Continuation on stable dosing regimens	Persistence offsets some unit price erosion
Competitive substitution	Uptake of other somatostatin analogs	Shifts addressable spend across long-acting options

How does manufacturing and supply economics affect trajectory?

Octreotide acetate’s manufacturing and formulation complexity shape financial outcomes:

• Depot formulations require stringent release and controlled delivery mechanics, which can limit effective competition speed even when regulatory approvals exist.
• IR formulations are generally more straightforward, so price competition can be faster once substitutes are on-formulary.
• Batch continuity and pharmacovigilance can create supply stability benefits for manufacturers with robust operations, supporting payer confidence.

What does this imply for revenue sustainability over the next lifecycle period?

In a mature category, octreotide acetate typically sustains revenue primarily through:

• chronic indication duration,
• depot regimen persistence,
• and ongoing clinician preference within established treatment algorithms.

Revenue sustainability usually declines in two steps:

• first, pricing compression after generic substitution,
• then, incremental erosion when competitors gain formulary share.

How should businesses model financial trajectory under realistic adoption curves?

A practical modeling approach for octreotide acetate uses scenario-based adoption curves tied to:

• regulatory launch timing by dosage form and geography,
• payer reimbursement and switching probabilities,
• and expected depot-versus-IR mix shift.

Core modeling logic

• Start from baseline demand in chronic indications.
• Apply net price declines proportional to generic penetration.
• Apply slower substitution rates for depot products versus IR.
• Include competitive pressure from other long-acting somatostatin analogs.

What are the investment and R&D implications?

For R&D portfolios and commercial strategy, octreotide acetate offers two actionable takeaways:

• Depot differentiation remains the main economic lever. Formulation improvements that improve tolerability, dosing schedule, or patient persistence can preserve pricing power even as molecule-level exclusivity fades.
• Lifecycle strategy should treat each dosage form as a distinct commercial asset. Exclusivity and substitution dynamics are not uniform across IR and depot products.

Market dynamics snapshot

• Demand is anchored by chronic endocrine and NET treatment settings.
• Long-acting depot formulations drive relative stability versus IR.
• Pricing compresses after generic entry, with depot substitution slower than IR.
• Competitive long-acting somatostatin analogs can shift share within endocrine and oncology sequencing.

---

Key Takeaways

• Octreotide acetate is a mature somatostatin analog category with chronic demand drivers, but pricing declines generally dominate financial trajectory over time.
• Depot formulations create commercial resilience via adherence and formulary stickiness, slowing the speed of net price erosion compared with IR.
• Financial outcomes depend less on molecule-level maturity and more on per-formulation exclusivity, substitution rules, and payer behavior by geography and strength.
• The most important monitoring variables are depot-to-IR mix, net price trends post-generic entry, formulary status in NET/endocrine pathways, and persistence on stable regimens.

---

FAQs

1) Is octreotide acetate’s demand primarily driven by oncology or endocrine?

Demand spans both oncology (NET-related use) and endocrine (including acromegaly), with chronic therapy duration supporting baseline volume.

2) Do depot formulations protect revenue better than immediate-release octreotide?

Yes. Depot products typically show slower substitution and more stable adherence-driven persistence than IR products.

3) What usually causes revenue declines in mature octreotide markets?

Unit net price compression after generic entry and payer-driven formulary substitution, with competitive long-acting somatostatin analogs as a secondary pressure.

4) Does competitive pressure come from within the same drug class?

Yes. Other long-acting somatostatin analog therapies compete for formulary placement and share in NET and endocrine treatment pathways.

5) What is the most actionable KPI for monitoring octreotide acetate trajectory?

The depot-to-IR mix trend paired with net price changes by dosage form and geography.

---

References

[1] FDA. (n.d.). Drug approvals and information (octreotide acetate products). U.S. Food and Drug Administration. https://www.fda.gov/
[2] EMA. (n.d.). European public assessment reports and product information (octreotide acetate). European Medicines Agency. https://www.ema.europa.eu/
[3] National Cancer Institute. (n.d.). Neuroendocrine tumors treatment (somatostatin analogs). U.S. National Institutes of Health. https://www.cancer.gov/